Omalizumab as a Therapeutic Option for Nasal Polyposis in Moderate-to-Severe Persistent Allergic Asthma: Evidence From a Prospective Study in a Real-World Setting

J Investig Allergol Clin Immunol. 2020;30(6):470-472. doi: 10.18176/jiaci.0602. Epub 2020 Jun 3.

J Ruiz-Hornillos^{1

2

3}, B Rodríguez Jiménez⁴, A Feliu Vila⁵, A Moreno Fernández⁶, M J Hernández García⁷, J Domínguez-Ortega^{8

9}; on behalf the ESPLORA group

¹ Allergy Department, Infanta Elena University Hospital, Valdemoro, Spain.
² School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
³ Health Research Institute-Fundación Jiménez Díaz University Hospital (IIS-FJD), Madrid, Spain.
⁴ Allergy Department, University Hospital of Getafe, Getafe, Spain.
⁵ Allergy Department, Tajo University Hospital, Aranjuez, Spain.
⁶ Allergy Department, Virgen de la Luz Hospital, Cuenca, Spain.
⁷ Otorhinolaryngology Department, Infanta Elena University Hospital, Valdemoro, Spain.
⁸ Allergy Department, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
⁹ CIBER Respiratory Diseases, CIBERES, Madrid, Spain.

No abstract available

Keywords: Moderate-to-severe persistent allergic asthma; Nasal polyposis; Omalizumab; Prospective study; Real-world.

MeSH terms